Epidemiology
Nonalcoholic fatty liver disease (NAFLD) is an accumulation of fat in the liver (hepatic steatosis). NAFLD without inflammation is nonalcoholic fatty liver (NAFL), while the presence of inflammation indicates nonalcoholic steatohepatitis (NASH). 1 An examination of data from National Health and Nutrition Examination Survey (NHANES) suggests an increase of NAFLD to an estimated prevalence of 19%, representing almost 29 million adult patients. The most common risk factors include diabetes, metabolic syndrome, dyslipidemia, and obesity. NAFLD is also more prevalent in male patients and Mexican Americans. 2 An analysis of the economic impact of NAFLD estimated an annual cost of $103 billion. If societal costs are included, the total is estimated to be $292 billion. However, this analysis used a higher prevalence than the NHANES analysis. 3 Outpatient treatment of NAFLD patients is estimated to be $9,011, while hospitalized patients have an average cost of $36,289. About one-third of NAFLD patients have fibrosis progression with NASH patients progressing twice as fast as NAFL patients (7 vs 14 years). 4 
Current Treatment
There are currently no approved drugs to treat NAFLD or NASH. It is estimated that 11% of patients with hepatic steatosis may be at high risk for hepatic fibrosis. Treatment for NASH currently consists of weight loss through diet and exercise. Weight loss was shown to decrease steatosis. A 7% to 10% decrease in weight has been shown to improve the NAFLD activity score. 5 Bariatric surgery may also be considered for weight loss in noncirrhotic patients. Patients are advised to avoid heavy use of alcohol. The effect of low or moderate alcohol use is unknown. The most recent guidelines from the American Association for the Study of Liver Diseases (AASLD) states that NAFLD patients are at a higher risk for cardiovascular complications. Therefore, statins are recommended to lower hyperlipidemia in NAFLD. Statins can also be used in patients with NASH without decompensated cirrhosis. Pioglitazone and vitamin E can be used in patients with biopsy-proven NASH to improve liver histology. Vitamin E should not be used in diabetic patients with NASH, NASH cirrhosis, or cryptogenic cirrhosis. Neither drug should be used in patients with NAFLD without liver biopsy. 6 
New Treatment Options
With no approved drugs and limitations with current treatments, there has been an increase in the development of therapies for NASH. While many drugs are in early stages of development, a few are in mid to late stages (Table 1) . These drugs are for the treatment of NAFLD that has progressed to NASH. There are currently no drugs in late-stage development to prevent NASH from developing in highrisk NAFLD patients. Some drugs target a reduction in liver fat, while other drugs target liver pathology such as fibrosis or inflammation.
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